These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2478560)

  • 21. Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines.
    Coradini D; Biffi A; Pellizzaro C; Pirronello E; Di Fronzo G
    Tumour Biol; 1997; 18(1):22-9. PubMed ID: 8989922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination.
    Adam L; Crépin M; Isräel L
    Cancer Res; 1997 Mar; 57(6):1023-9. PubMed ID: 9067263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic cytotoxic effects of tumor necrosis factor, interferon-gamma and tamoxifen on breast cancer cell lines.
    Matsuo S; Takano S; Yamashita J; Ogawa M
    Anticancer Res; 1992; 12(5):1575-9. PubMed ID: 1444224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
    Mai Z; Blackburn GL; Zhou JR
    Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study.
    Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
    Oncol Rep; 2009 Apr; 21(4):1011-6. PubMed ID: 19288002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study.
    Recchia F; Sica G; de Filippis S; Discepoli S; Rea S; Torchio P; Frati L
    J Interferon Cytokine Res; 1995 Jul; 15(7):605-10. PubMed ID: 7553230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon.
    Werner A; Bender E; Mahaffey W; McKeating J; Marrangoni A; Katoh A
    Anticancer Drugs; 1996 May; 7(3):307-11. PubMed ID: 8792005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autocrine interferon-γ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor β subtype.
    Niu XL; Wang Y; Yao Z; Duan H; Li Z; Liu W; Zhang H; Deng WM
    Oncol Rep; 2015 Dec; 34(6):3120-30. PubMed ID: 26397740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells.
    Bezwoda WR; Meyer K
    Cancer Res; 1990 Sep; 50(17):5387-91. PubMed ID: 2386944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
    Kars A; Baltali E; Tekuzman G; Firat D; Alakavuklar M
    J Chemother; 1989 Jul; 1(4 Suppl):1196-7. PubMed ID: 16312831
    [No Abstract]   [Full Text] [Related]  

  • 33. [Present status of endocrine therapy of breast cancer: a surgeon's view].
    Nomura Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of OK-432 (picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432.
    Aoyagi H; Iino Y; Takeo T; Horii Y; Morishita Y; Horiuchi R
    Oncology; 1997; 54(5):414-23. PubMed ID: 9260604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro.
    Mannal P; McDonald D; McFadden D
    Am J Surg; 2010 Nov; 200(5):577-80. PubMed ID: 21056131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
    Garin AM; Dmitrieva NV; Vyshinskaia GV; Lichintser MR
    Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The present status of the adjuvant endocrine treatment.
    Jonat W; Maass H
    J Steroid Biochem; 1987; 27(1-3):499-502. PubMed ID: 3320540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of alpha-, beta- and gamma-interferon on the growth of breast cancer cell lines.
    Coradini D; Biffi A; Pirronello E; Di Fronzo G
    Anticancer Res; 1994; 14(5A):1779-84. PubMed ID: 7531412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.